Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs

Taylor T Schwartz, Hanke Zheng, Laetitia N’Dri, Sang Hee Park, Kristofer Norris, Vardhaman A Patel, Scott B Robinson, Keith Wittstock, Vadim Khaychuk, Alison R Silverstein, Jeffrey A Sparks · 2026

Read Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs by Taylor T Schwartz, Hanke Zheng, Laetitia N’Dri, Sang Hee Park, Kristofer Norris, Vardhaman A Patel, Scott B Robinson, Keith Wittstock, Vadim Khaychuk, Alison R Silverstein, Jeffrey A Sparks (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13624238.txt.

Description

Taylor T Schwartz leads a 2026 Medicare study comparing how long rheumatoid arthritis patients stay on their first advanced drug, a real-world sign of whether a treatment works and is tolerated. The patients studied all carried two antibody markers linked to harder disease, and earlier trials hinted that one drug, abatacept, might suit them especially well.

Using full Medicare claims linked to lab results from 2012 to 2019, the team followed 3,105 patients. They started abatacept, a tumour necrosis factor blocker, or a JAK inhibitor as their first advanced therapy. Twelve months later, about forty-eight percent of the abatacept group were still on their drug, against a third of the blocker group and just under forty percent of the JAK group. Statistical modelling confirmed the gap. The authors suggest antibody results deserve a place in choosing a first drug for these patients.

Catalog record

CREATORTaylor T Schwartz, Hanke Zheng, Laetitia N’Dri, Sang Hee Park, Kristofer Norris, Vardhaman A Patel, Scott B Robinson, Keith Wittstock, Vadim Khaychuk, Alison R Silverstein, Jeffrey A Sparks
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13624238

Browse the full library · About the Tower of Babel